Regenerx Biopharmaceuticals Inc (RGRX) 0.1359 $RGRX
Epidermolysis Bullosa - Pipeline Review, H1 2014
M2 - Wed Jul 30, 3:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xjhcc9/epidermolysis) has announced the addition of the "Epidermolysis Bullosa - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Epidermolysis Bullosa, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epidermolysis Bullosa and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Epidermolysis Bullosa - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Epidermolysis Bullosa pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - RegeneRx Biopharmaceuticals, Inc. - Fibrocell Science, Inc. - Birken AG - Scioderm, Inc. For more information visit http://www.researchandmarkets.com/research/xj...dermolysis
New Report: Thymosin B4 Prevents Heart Rupture & Improves Cardiac Function after Heart Attack in Mice
Business Wire - Tue Jul 15, 8:02AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" or "RegeneRx"
today announced that a new paper entitled, Thymosin B4 Prevents Cardiac Rupture and Improves Cardiac Function in Mice with Myocardial Infarction, was published in the journal, Heart Circulation Physiology, on July 11, 2014. "The present study shows for the first time that 1) TB4 is able to reduce incidence of cardiac rupture post-MI [myocardial infarction or heart attack] and markedly improved cardiac function at 5 weeks after MI, and that 2) the cardiac protective effects of TB4 after MI were associated with a significant reduction of excessive inflammatory response and cardiomyocyte apoptosis as well as with an enhancement of angiogenesis. From a clinical point of view, TB4 could potentially be a therapeutic candidate for patients with acute MI," according to the study's authors.
RegeneRx's Strategic Partner G-treeBNT Preparing for Phase III Dry Eye Trials in Asia with RGN-259
Business Wire - Mon Jul 07, 7:30AM CDT
RegeneRx Pharmaceuticals (OTCBB:RGRX), and G-treeBNT Co. Ltd., a Korean biotech firm, jointly announced today that G-treeBNT is preparing to file an IND and sponsor a Phase III clinical trial with RGN-259 (a Thymosin Beta 4-based preservative-free eye drop) in patients with moderate to severe dry eye initially in South Korea, followed by Japan and Australia, with follow-on registrations in certain additional Asian and Pacific Rim countries if appropriate.
RegeneRx and Lee's Pharmaceutical Dry Eye Drug Progresses - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 11:10AM CDT
RegeneRx Biopharmaceuticals, Inc. (RGRX) and Lee's Pharmaceutical announced that the Chinese regulatory authority has accepted a phase II investigational new drug application for RGN-259.
RegeneRx Biopharmaceuticals to begin Phase 2 trial of RGN-259 in dry eye syndrome patients in China in Q1 2015
M2 - Mon Jun 23, 5:25AM CDT
Novel therapeutic company RegeneRx Biopharmaceuticals (Other OTC:RGRX) and Lee's Pharmaceutical Holdings jointly announced on Friday that they will begin the Phase II IND for RGN-259 in patients with moderate to severe dry eye syndrome in China.
Chinese FDA Accepts Phase 2 IND for RGN-259 for Dry Eye
Business Wire - Sun Jun 22, 11:00PM CDT
RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("RegeneRx" and Lee's Pharmaceutical Holdings Ltd. ("Lee's" today jointly announced that the Chinese FDA has accepted a Phase II IND for RGN-259 (thymosin beta 4-based, preservative-free eye drops) to be tested in patients with moderate to severe dry eye syndrome in China.
RegeneRx wins USD1.35m under product license and securities purchase agreement
M2 - Mon Mar 31, 5:42AM CDT
US-based RegeneRx Biopharmaceuticals (Other OTC:RGRX) reported on Friday the receipt of the initial USD1.35m payment pursuant to its product license and securities purchase agreement with G-treeBNT Co headquartered in Gyeonggi-do, Korea
RegeneRx Receives $1.35 Million Pursuant to Product License And Stock Purchase Agreement
Business Wire - Fri Mar 28, 12:27PM CDT
RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" or "RegeneRx" today announced that it received the initial $1.35 million payment pursuant to its product license and securities purchase agreement with G-treeBNT Co., Ltd (formerly Digital Aria Co., Ltd.), headquartered in Gyeonggi-do, Korea, for G-treeBNT to develop RegeneRx's RGN-259 preservative-free eye drop product candidate in Asia (excluding China, Hong Kong, Taiwan, and Macau), and its RGN-137 topical dermal gel product candidate in the U.S. G-treeBNT purchased stock at $0.12 per share, is obligated to make an additional equity investment of $1.0 million at $0.12 per share by August 31, 2014 and retains an option until January 31, 2015 to purchase additional common stock for $825,000 at $0.15 per share. The licensing and securities purchase agreements will be filed as exhibits to the Company's Quarterly Report on Form 10-Q for the quarter ending March 31, 2014.
RegeneRx and Digital Aria Sign Product License and Stock Purchase Agreements
Business Wire - Fri Mar 07, 6:57AM CST
RegeneRx Biopharmaceuticals, Inc. (OTC:RGRX) ("the Company" or "RegeneRx" today announced that it has entered into two product license agreements with Digital Aria Co., Ltd., headquartered in Gyeonggi-do, Korea, for Digital Aria to develop RegeneRx's RGN-259 preservative-free eye drop product candidate in Asia (excluding China, Hong Kong, Taiwan, and Macau), and its RGN-137 topical dermal gel product candidate in the U.S. Digital Aria will also make an equity investment into RegeneRx of $2.35 million enabling RegeneRx to move forward with its ophthalmic clinical program, and retains a 10-month option to purchase additional common stock for $825,000.
RegeneRx Biopharmaceuticals wins patent for Thymosin beta 4 for treating Dry Eye Syndrome in Israel
M2 - Tue Feb 25, 5:44AM CST
Biopharmaceutical company RegeneRx Biopharmaceuticals (Other OTC:RGRX) reported on Monday the receipt of patent for Thymosin beta 4 in Israel.
RegeneRx Receives Israeli Patent for Treatment of Dry Eye Syndrome
Business Wire - Mon Feb 24, 9:00AM CST
RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" or "RegeneRx" today announced that it has received an Israeli patent for the treatment of Dry Eye Syndrome using Thymosin beta 4 (TB4) and various fragments of TB4, as well as other analogues and derivatives. The patent will expire in 2026.
RegeneRx Biopharmaceuticals Inc awarded patent allowance in the US for neuro and muscular degenerative diseases
M2 - Fri Jan 17, 10:38AM CST
RegeneRx Biopharmaceuticals Inc (RGRX) revealed on Thursday that it has received a Notice of Allowance of a US patent application for using novel therapeutic peptide for the prevention and treatment of neuro and muscular degenerative diseases and related tissue damage.
RegeneRx Receives Notice of Allowance from U.S. Patent Office for Treatment and Prevention of Neuro and Muscular Degenerative Diseases
Business Wire - Thu Jan 16, 7:30AM CST
RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" or "RegeneRx" today announced that it has received a Notice of Allowance of a U.S. patent application for using Thymosin beta 4 (TB4) and various fragments and other related peptides for the prevention and treatment of neuro and muscular degenerative diseases and related tissue damage. The patent will expire in 2026.
RegeneRx Biopharmaceuticals Inc awarded orphan drug designation for TB4 for treating Neurotrophic Keratopathy in the US
M2 - Mon Jan 06, 4:56AM CST
Novel therapeutic peptide developer RegeneRx Biopharmaceuticals Inc (OTC Markets:RGRX) reported on Friday the receipt of the orphan drug designation for its drug candidate, Thymosin beta 4 (T?4), for the treatment of Neurotrophic Keratopathy (NK), a serious degenerative disease of the corneal epithelium, in the US.
RegeneRx Receives Orphan Drug Designation for TB4 in the Treatment of Neurotrophic Keratopathy
Business Wire - Fri Jan 03, 7:21AM CST
RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" or "RegeneRx" announced that it has received Orphan Drug designation from U.S. FDA's Office of Orphan Products Development (OOPD) for its drug candidate, Thymosin beta 4 (TB4), for the treatment of Neurotrophic Keratopathy (NK), a serious degenerative disease of the corneal epithelium (the outside layer of the eye). A reduction in corneal sensitivity or complete corneal anesthesia is the hallmark of this disease and is responsible for producing corneal ulceration, perforation, pain and impaired vision. The designation, for novel drugs to treat diseases with a prevalence of less than 200,000 patients in the U.S., provides seven years of extended marketing exclusivity, waiver of FDA user fees, tax credits of up to 50% of qualified clinical trial expenses, and eligibility of FDA research grants for clinical trials.
RegeneRx Biopharmaceuticals Inc secures Notice of Allowance for reversal of skin aging product in Canada
M2 - Mon Dec 23, 7:26AM CST
RegeneRx Biopharmaceuticals Inc (Other OTC:RGRX) reported on Friday the receipt of a Notice of Allowance of a Canadian patent application for using Thymosin beta 4 (T?4) and various fragments and other related peptides for inhibiting or reversing skin aging.
RegeneRx Receives Notice of Allowance from Canadian Patent Office for Reversal of Skin Aging
Business Wire - Fri Dec 20, 11:01AM CST
RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" or "RegeneRx" today announced that it has received a Notice of Allowance of a Canadian patent application for using Thymosin beta 4 (TB4) and various fragments and other related peptides for inhibiting or reversing skin aging. The patent will expire in 2021.
RegeneRx Releases Results of Phase 2 Clinical Trial on Patients with Epidermolysis Bullosa
Business Wire - Mon Jun 24, 7:30AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) ("the Company" or "RegeneRx" today announced results from its dose-escalating, double-blind, placebo-controlled Phase 2 clinical trial in 30 patients with dystrophic and junctional epidermolysis bullosa (EB), a severe "orphan" skin disorder with limited prevalence in the U.S. and Europe. RGN-137 (a topical formulation of Thymosin beta 4 or TB4) was administered to a single non-healing index lesion in these patients daily for 56 days and followed for an additional 14 days post-treatment.
Global Epidermolysis Bullosa - Pipeline Review Report, H1 2013
M2 - Fri Jun 21, 5:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hrf76c/epidermolysis) has announced the addition of the "Epidermolysis Bullosa - Pipeline Review, H1 2013" report to their offering. 'Epidermolysis Bullosa - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Epidermolysis Bullosa, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Epidermolysis Bullosa. Scope - A snapshot of the global therapeutic scenario for Epidermolysis Bullosa. - A review of the Epidermolysis Bullosa products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis
Skin Ulcers - Pipeline Review, H1 2013: A Feature on Pipeline Projects On the Basis of Monotherapy and Combined Therapeutics
M2 - Tue Jun 04, 11:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gd363b/skin_ulcers) has announced the addition of the "Skin Ulcers - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Skin Ulcers - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Skin Ulcers, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Skin Ulcers. Skin Ulcers - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Skin Ulcers. - A review of the Skin Ulcers products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - Coverage of the Skin Ulcers pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Nanotherapeutics, Inc. - Henry Ford Health System - Galderma S.A. - RegeneRx Biopharmaceuticals, Inc. - EyeGene, Inc. For more information visit http://www.researchandmarkets.com/research/gd...kin_ulcers About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Epidermolysis Bullosa - Pipeline Review, H1 2014
M2 - Wed Jul 30, 3:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xjhcc9/epidermolysis) has announced the addition of the "Epidermolysis Bullosa - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Epidermolysis Bullosa, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epidermolysis Bullosa and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Epidermolysis Bullosa - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Epidermolysis Bullosa pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - RegeneRx Biopharmaceuticals, Inc. - Fibrocell Science, Inc. - Birken AG - Scioderm, Inc. For more information visit http://www.researchandmarkets.com/research/xj...dermolysis
New Report: Thymosin B4 Prevents Heart Rupture & Improves Cardiac Function after Heart Attack in Mice
Business Wire - Tue Jul 15, 8:02AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" or "RegeneRx"
today announced that a new paper entitled, Thymosin B4 Prevents Cardiac Rupture and Improves Cardiac Function in Mice with Myocardial Infarction, was published in the journal, Heart Circulation Physiology, on July 11, 2014. "The present study shows for the first time that 1) TB4 is able to reduce incidence of cardiac rupture post-MI [myocardial infarction or heart attack] and markedly improved cardiac function at 5 weeks after MI, and that 2) the cardiac protective effects of TB4 after MI were associated with a significant reduction of excessive inflammatory response and cardiomyocyte apoptosis as well as with an enhancement of angiogenesis. From a clinical point of view, TB4 could potentially be a therapeutic candidate for patients with acute MI," according to the study's authors. RegeneRx's Strategic Partner G-treeBNT Preparing for Phase III Dry Eye Trials in Asia with RGN-259
Business Wire - Mon Jul 07, 7:30AM CDT
RegeneRx Pharmaceuticals (OTCBB:RGRX), and G-treeBNT Co. Ltd., a Korean biotech firm, jointly announced today that G-treeBNT is preparing to file an IND and sponsor a Phase III clinical trial with RGN-259 (a Thymosin Beta 4-based preservative-free eye drop) in patients with moderate to severe dry eye initially in South Korea, followed by Japan and Australia, with follow-on registrations in certain additional Asian and Pacific Rim countries if appropriate.
RegeneRx and Lee's Pharmaceutical Dry Eye Drug Progresses - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 11:10AM CDT
RegeneRx Biopharmaceuticals, Inc. (RGRX) and Lee's Pharmaceutical announced that the Chinese regulatory authority has accepted a phase II investigational new drug application for RGN-259.
RegeneRx Biopharmaceuticals to begin Phase 2 trial of RGN-259 in dry eye syndrome patients in China in Q1 2015
M2 - Mon Jun 23, 5:25AM CDT
Novel therapeutic company RegeneRx Biopharmaceuticals (Other OTC:RGRX) and Lee's Pharmaceutical Holdings jointly announced on Friday that they will begin the Phase II IND for RGN-259 in patients with moderate to severe dry eye syndrome in China.
Chinese FDA Accepts Phase 2 IND for RGN-259 for Dry Eye
Business Wire - Sun Jun 22, 11:00PM CDT
RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("RegeneRx"
and Lee's Pharmaceutical Holdings Ltd. ("Lee's" today jointly announced that the Chinese FDA has accepted a Phase II IND for RGN-259 (thymosin beta 4-based, preservative-free eye drops) to be tested in patients with moderate to severe dry eye syndrome in China. RegeneRx wins USD1.35m under product license and securities purchase agreement
M2 - Mon Mar 31, 5:42AM CDT
US-based RegeneRx Biopharmaceuticals (Other OTC:RGRX) reported on Friday the receipt of the initial USD1.35m payment pursuant to its product license and securities purchase agreement with G-treeBNT Co headquartered in Gyeonggi-do, Korea
RegeneRx Receives $1.35 Million Pursuant to Product License And Stock Purchase Agreement
Business Wire - Fri Mar 28, 12:27PM CDT
RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" or "RegeneRx"
today announced that it received the initial $1.35 million payment pursuant to its product license and securities purchase agreement with G-treeBNT Co., Ltd (formerly Digital Aria Co., Ltd.), headquartered in Gyeonggi-do, Korea, for G-treeBNT to develop RegeneRx's RGN-259 preservative-free eye drop product candidate in Asia (excluding China, Hong Kong, Taiwan, and Macau), and its RGN-137 topical dermal gel product candidate in the U.S. G-treeBNT purchased stock at $0.12 per share, is obligated to make an additional equity investment of $1.0 million at $0.12 per share by August 31, 2014 and retains an option until January 31, 2015 to purchase additional common stock for $825,000 at $0.15 per share. The licensing and securities purchase agreements will be filed as exhibits to the Company's Quarterly Report on Form 10-Q for the quarter ending March 31, 2014. RegeneRx and Digital Aria Sign Product License and Stock Purchase Agreements
Business Wire - Fri Mar 07, 6:57AM CST
RegeneRx Biopharmaceuticals, Inc. (OTC:RGRX) ("the Company" or "RegeneRx"
today announced that it has entered into two product license agreements with Digital Aria Co., Ltd., headquartered in Gyeonggi-do, Korea, for Digital Aria to develop RegeneRx's RGN-259 preservative-free eye drop product candidate in Asia (excluding China, Hong Kong, Taiwan, and Macau), and its RGN-137 topical dermal gel product candidate in the U.S. Digital Aria will also make an equity investment into RegeneRx of $2.35 million enabling RegeneRx to move forward with its ophthalmic clinical program, and retains a 10-month option to purchase additional common stock for $825,000. RegeneRx Biopharmaceuticals wins patent for Thymosin beta 4 for treating Dry Eye Syndrome in Israel
M2 - Tue Feb 25, 5:44AM CST
Biopharmaceutical company RegeneRx Biopharmaceuticals (Other OTC:RGRX) reported on Monday the receipt of patent for Thymosin beta 4 in Israel.
RegeneRx Receives Israeli Patent for Treatment of Dry Eye Syndrome
Business Wire - Mon Feb 24, 9:00AM CST
RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" or "RegeneRx"
today announced that it has received an Israeli patent for the treatment of Dry Eye Syndrome using Thymosin beta 4 (TB4) and various fragments of TB4, as well as other analogues and derivatives. The patent will expire in 2026. RegeneRx Biopharmaceuticals Inc awarded patent allowance in the US for neuro and muscular degenerative diseases
M2 - Fri Jan 17, 10:38AM CST
RegeneRx Biopharmaceuticals Inc (RGRX) revealed on Thursday that it has received a Notice of Allowance of a US patent application for using novel therapeutic peptide for the prevention and treatment of neuro and muscular degenerative diseases and related tissue damage.
RegeneRx Receives Notice of Allowance from U.S. Patent Office for Treatment and Prevention of Neuro and Muscular Degenerative Diseases
Business Wire - Thu Jan 16, 7:30AM CST
RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" or "RegeneRx"
today announced that it has received a Notice of Allowance of a U.S. patent application for using Thymosin beta 4 (TB4) and various fragments and other related peptides for the prevention and treatment of neuro and muscular degenerative diseases and related tissue damage. The patent will expire in 2026. RegeneRx Biopharmaceuticals Inc awarded orphan drug designation for TB4 for treating Neurotrophic Keratopathy in the US
M2 - Mon Jan 06, 4:56AM CST
Novel therapeutic peptide developer RegeneRx Biopharmaceuticals Inc (OTC Markets:RGRX) reported on Friday the receipt of the orphan drug designation for its drug candidate, Thymosin beta 4 (T?4), for the treatment of Neurotrophic Keratopathy (NK), a serious degenerative disease of the corneal epithelium, in the US.
RegeneRx Receives Orphan Drug Designation for TB4 in the Treatment of Neurotrophic Keratopathy
Business Wire - Fri Jan 03, 7:21AM CST
RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" or "RegeneRx"
announced that it has received Orphan Drug designation from U.S. FDA's Office of Orphan Products Development (OOPD) for its drug candidate, Thymosin beta 4 (TB4), for the treatment of Neurotrophic Keratopathy (NK), a serious degenerative disease of the corneal epithelium (the outside layer of the eye). A reduction in corneal sensitivity or complete corneal anesthesia is the hallmark of this disease and is responsible for producing corneal ulceration, perforation, pain and impaired vision. The designation, for novel drugs to treat diseases with a prevalence of less than 200,000 patients in the U.S., provides seven years of extended marketing exclusivity, waiver of FDA user fees, tax credits of up to 50% of qualified clinical trial expenses, and eligibility of FDA research grants for clinical trials. RegeneRx Biopharmaceuticals Inc secures Notice of Allowance for reversal of skin aging product in Canada
M2 - Mon Dec 23, 7:26AM CST
RegeneRx Biopharmaceuticals Inc (Other OTC:RGRX) reported on Friday the receipt of a Notice of Allowance of a Canadian patent application for using Thymosin beta 4 (T?4) and various fragments and other related peptides for inhibiting or reversing skin aging.
RegeneRx Receives Notice of Allowance from Canadian Patent Office for Reversal of Skin Aging
Business Wire - Fri Dec 20, 11:01AM CST
RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" or "RegeneRx"
today announced that it has received a Notice of Allowance of a Canadian patent application for using Thymosin beta 4 (TB4) and various fragments and other related peptides for inhibiting or reversing skin aging. The patent will expire in 2021. RegeneRx Releases Results of Phase 2 Clinical Trial on Patients with Epidermolysis Bullosa
Business Wire - Mon Jun 24, 7:30AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) ("the Company" or "RegeneRx"
today announced results from its dose-escalating, double-blind, placebo-controlled Phase 2 clinical trial in 30 patients with dystrophic and junctional epidermolysis bullosa (EB), a severe "orphan" skin disorder with limited prevalence in the U.S. and Europe. RGN-137 (a topical formulation of Thymosin beta 4 or TB4) was administered to a single non-healing index lesion in these patients daily for 56 days and followed for an additional 14 days post-treatment. Global Epidermolysis Bullosa - Pipeline Review Report, H1 2013
M2 - Fri Jun 21, 5:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hrf76c/epidermolysis) has announced the addition of the "Epidermolysis Bullosa - Pipeline Review, H1 2013" report to their offering. 'Epidermolysis Bullosa - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Epidermolysis Bullosa, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Epidermolysis Bullosa. Scope - A snapshot of the global therapeutic scenario for Epidermolysis Bullosa. - A review of the Epidermolysis Bullosa products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis
Skin Ulcers - Pipeline Review, H1 2013: A Feature on Pipeline Projects On the Basis of Monotherapy and Combined Therapeutics
M2 - Tue Jun 04, 11:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gd363b/skin_ulcers) has announced the addition of the "Skin Ulcers - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Skin Ulcers - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Skin Ulcers, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Skin Ulcers. Skin Ulcers - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Skin Ulcers. - A review of the Skin Ulcers products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - Coverage of the Skin Ulcers pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Nanotherapeutics, Inc. - Henry Ford Health System - Galderma S.A. - RegeneRx Biopharmaceuticals, Inc. - EyeGene, Inc. For more information visit http://www.researchandmarkets.com/research/gd...kin_ulcers About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
